ArticlePharmaceutics2020
Repositioning
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Synthesis and Optimization of PEG-PLGA Immunotherapeutic Nanoparticles for the Controlled Release of IFNα.AAPS PharmSciTech · 2026Article
- Formulation Feasibility of a Mechanically Compliant Stearate Organogel-Methylcellulose/Gelatin Bigel for Localized Neurotherapeutic Delivery.Gels (Basel, Switzerland) · 2026Article
- A New Treatment Approach for Tympanic Membrane Repair: Stabilization of Fascia Grafts Using a PLGA-Based Tissue Stabilizer.Polymers · 2026Article
- Coaxial nanofiber design for traumatic brain injury: a review and framework for phase-responsive therapeutics.Discover nano · 2026Review
- Trends and Advancements in Smart Electrospun Food Fibers for the Management of Neurological Disorders.CNS & neurological disorders drug targets · 2026Review
- Synthesis and Characterization of Bioactive Oligoitaconates with Amino Acid Functional Groups for Tissue Engineering.International journal of molecular sciences · 2025Article
- Design of Cysteine Functional Polyesters through Michael Addition.Scientific reports · 2025Article
- Inhalable N-Acetylcysteine-loaded Lactose-coated PLGA Nanoparticles for Tuberculosis Treatment.Pharmaceutical research · 2025Article
- 3D printing of interferon γ-preconditioned NSC-derived exosomes/collagen/chitosan biological scaffolds for neurological recovery after TBI.Bioactive materials · 2024Article
- Recent progresses in neural tissue engineering using topographic scaffolds.American journal of stem cells · 2024Review
- Review
- Integrated printed BDNF-stimulated HUCMSCs-derived exosomes/collagen/chitosan biological scaffolds with 3D printing technology promoted the remodelling of neural networks after traumatic brain injury.Regenerative biomaterials · 2023Article
- Antioxidative NAC-Loaded Silk Nanoparticles with Opening Mucosal Tight Junctions for Nasal Drug Delivery: An In Vitro and In Vivo Study.Pharmaceutics · 2022Article
- Targeting Molecular Mediators of Ferroptosis and Oxidative Stress for Neurological Disorders.Oxidative medicine and cellular longevity · 2022Review
- Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis:Current research in pharmacology and drug discovery · 2022Article
- Electrospun Membranes as a Porous Barrier for Molecular Transport: Membrane Characterization and Release Assessment.Pharmaceutics · 2021Article
- Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Traumatic brain injury (TBI) presents a serious challenge for modern medicine due to the poor regenerative capabilities of the brain, complex pathophysiology, and lack of effective treatment for TBI to date. Tissue-engineered scaffolds have shown some experimental success in vivo; unfortunately, none have yielded consummate results of clinical efficacy. N-acetylcysteine has shown neuroprotective potential. To this end, we developed a N-acetylcysteine (NAC)-loaded poly(lactic-co-glycolic acid) (PLGA) electrospun system for potential neural tissue application for TBI. Scanning electron microscopy showed nanofiber diameters ranging 72-542 nm and 124-592 nm for NAC-free and NAC-loaded PLGA nanofibers, respectively. NAC loading was obtained at 28%, and drug entrapment efficacy was obtained at 84%. A biphasic NAC release pattern that featured an initial burst release (13.9%) stage and a later sustained release stage was noted, thus enabling the prolonged replenishing of NAC and drastically improving cell viability and proliferation. This was evidenced by a significantly higher cell viability and proliferation on NAC-loaded nanofibers for rat pheochromocytoma (PC12) and human glioblastoma multiform (A172) cell lines in comparison to PLGA-only nanofibers. The increased cell viability and cell proliferation on NAC-loaded nanofiber substantiates for the repositioning of NAC as a pharmacological agent in neural tissue regeneration applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.